Xilio Therapeutics Inc (XLO) concluded trading on Wednesday at a closing price of $1.48, with 167.17 million shares of worth about $247.41 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 77.35% during that period and on February 12, 2025 the price saw a gain of about 125.27%. Currently the company’s common shares owned by public are about 43.96M shares, out of which, 19.62M shares are available for trading.
Stock saw a price change of 113.63% in past 5 days and over the past one month there was a price change of 34.55%. Year-to-date (YTD), XLO shares are showing a performance of 54.97% which increased to 134.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.50 but also hit the highest price of $1.93 during that period. The average intraday trading volume for Xilio Therapeutics Inc shares is 484.20K. The stock is currently trading 74.49% above its 20-day simple moving average (SMA20), while that difference is up 53.62% for SMA50 and it goes to 54.79% higher than SMA200.
Xilio Therapeutics Inc (NASDAQ: XLO) currently have 43.96M outstanding shares and institutions hold larger chunk of about 16.07% of that.
The stock has a current market capitalization of $67.72M and its 3Y-monthly beta is at -0.26. It has posted earnings per share of -$1.72 in the same period. It has Quick Ratio of 1.67 while making debt-to-equity ratio of 0.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XLO, volatility over the week remained 13.88% while standing at 12.03% over the month.
Analysts are in expectations that Xilio Therapeutics Inc (XLO) stock would likely to be making an EPS of -0.22 in the current quarter, while forecast for next quarter EPS is 0 and it is -0.22 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.22 which is -0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.64 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 59.04% while it is estimated to increase by 55.49% in next year. EPS is likely to grow at an annualized rate of 45.49% for next 5-years, compared to annual growth of -44.91% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Chardan Capital Markets on December 21, 2022 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by H.C. Wainwright stated Xilio Therapeutics Inc (XLO) stock as a Buy in their note to investors on January 10, 2022, suggesting a price target of $36 for the stock. On November 16, 2021, Raymond James Initiated their recommendations, while on November 16, 2021, Morgan Stanley Initiated their ratings for the stock with a price target of $32. Stock get a Buy rating from Guggenheim on November 16, 2021.
